Much of Tuesday's rally is on the backs of hedge funds who -- poorly positioned for the Wuhan coronavirus -- started shorting virus-related stocks right into Friday.
How bad could this get and how should investors should respond? Let's take a step back to find out.
Company has an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on coronavirus patients.
Here's how the stock might surprise Wall Street.
The Wuhan coronavirus has now infected more people than SARS ever did. The WHO's designation of a global public-health 'concern' helps, but China finds itself increasingly isolated.
AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.
Let's see if the two are in alignment.
The stock of the medical device maker has been stagnant for months and its charts have yet to prove themselves.
The charts of TMO are positive.
Here's how to play ALGN, which is expected to report later Wednesday, three weeks from its Feb. 21 expiration.